Biosimilars of filgrastim in autologous stem cell transplantation: certain differences for myeloma patients only

Christophe NicolService d'Hématologie, Institut de Cancéro-Hématologie, Hôpital Morvan, CHRU de Brest, Brest Cedex, France;

Chloé HenryService d'Onco-Pédiatrie, Hôpital Morvan, CHRU de Brest, Brest Cedex, France;

Marie-Anne CouturierService d'Hématologie, Institut de Cancéro-Hématologie, Hôpital Morvan, CHRU de Brest, Brest Cedex, France;

Pascal DelépineEtablissement Français du Sang, Site de Brest, CHRU de Brest, Brest Cedex, France;

Céline TripogneyEtablissement Français du Sang, Site de Brest, CHRU de Brest, Brest Cedex, France;

Caroline BuorsLaboratoire d'Hématologie, Hôpital de la Cavale Blanche, CHRU de Brest, Brest Cedex, France

Gaëlle GuillermService d'Hématologie, Institut de Cancéro-Hématologie, Hôpital Morvan, CHRU de Brest, Brest Cedex, France;

Christian BerthouService d'Hématologie, Institut de Cancéro-Hématologie, Hôpital Morvan, CHRU de Brest, Brest Cedex, France;

Adrian TempesculService d'Hématologie, Institut de Cancéro-Hématologie, Hôpital Morvan, CHRU de Brest, Brest Cedex, France;

Jean-Christophe IanottoService d'Hématologie, Institut de Cancéro-Hématologie, Hôpital Morvan, CHRU de Brest, Brest Cedex, France; Correspondence[email protected]

show all

Click to increase image sizeClick to decrease image size

Acknowledgements

The authors thank the center’s nurses for their help in collecting the clinical data. The authors received grants from Sandoz France to perform statistical analyses.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article online at http://10.1080/10428194.2017.1285025.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Biosimilars of filgrastim in autologous stem cell transplantation: certain differences for myeloma patients only

Information for

Open access

Opportunities

Help and information

Biosimilars of filgrastim in autologous stem cell transplantation: certain differences for myeloma patients only

Acknowledgements

Potential conflict of interest

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature